$CTKB
Cytek Biosciences, Inc. Stock $ctkb

$ctkb Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023005610 Filed on March 01, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$37.09M	$48.34M	$164.0M
YoY Change	5.77%	24.28%	28.2%
Cost Of Revenue	$16.05M	$18.96M	$63.06M
YoY Change	7.81%	24.28%	29.21%
Gross Profit	$21.04M	$29.37M	$101.0M
YoY Change	4.27%	24.28%	27.58%
Gross Profit Margin	56.72%	60.77%	61.56%
Selling, General & Admin	$23.23M	$19.54M	$67.92M
YoY Change	60.08%	28.21%	49.13%
% of Gross Profit	110.4%	66.53%	67.26%
Research & Development	$9.974M	$9.747M	$34.86M
YoY Change	24.29%	37.75%	42.62%
% of Gross Profit	47.41%	33.18%	34.52%
Depreciation & Amortization	$1.001M	$761.0K	$2.492M
YoY Change	26.07%	11.09%	100.64%
% of Gross Profit	4.76%	2.59%	2.47%
Operating Expenses	$33.20M	$29.29M	$102.8M
YoY Change	47.33%	31.23%	46.85%
Operating Profit	-$12.16M	$84.00K	-$1.804M
YoY Change	415.99%	-93.62%	-119.7%
Interest Expense	$673.0K	$1.939M	$2.573M
YoY Change	14.07%	-509.07%	47.79%
% of Operating Profit		2308.33%
Other Income/Expense, Net	$3.122M	$2.091M	$3.064M
YoY Change	-430.02%	-624.06%	-195.18%
Pretax Income	-$9.040M	$4.114M	$1.260M
YoY Change	173.69%	826.58%	-78.78%
Income Tax	-$2.233M	$396.0K	-$1.224M
% Of Pretax Income		9.63%	-97.14%
Net Earnings	-$6.807M	$3.529M	$2.484M
YoY Change	215.43%	-396.31%	-17.94%
Net Earnings / Revenue	-18.35%	7.3%	1.51%
Basic Earnings Per Share			$0.02
Diluted Earnings Per Share	-$0.05	$0.02	$0.02
COMMON SHARES
Basic Shares Outstanding	135.4M	134.9M	134.5M
Diluted Shares Outstanding	135.5M		138.6M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$299.0M	$341.1M	$341.1M
YoY Change	-17.51%	-6.44%	-6.44%
Cash & Equivalents	$129.5M	$296.6M	$173.2M
Short-Term Investments	$169.5M	$44.55M	$44.55M
Other Short-Term Assets	$1.422M	$3.796M	$13.84M
YoY Change	-15.16%	436.16%	160.63%
Inventory	$69.50M	$48.15M	$48.15M
Prepaid Expenses
Receivables	$43.10M	$48.86M	$48.86M
Other Receivables	$2.011M	$2.011M	$2.011M
Total Short-Term Assets	$425.6M	$454.0M	$454.0M
YoY Change	-3.07%	5.16%	5.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.55M	$13.68M	$27.57M
YoY Change	139.07%	133.84%	371.12%
Goodwill	$19.14M	$10.14M
YoY Change	88.71%	0.0%
Intangibles	$24.66M	$4.331M
YoY Change	469.87%	-8.61%
Long-Term Investments	$1.600M	$1.600M
YoY Change
Other Assets	$3.006M	$2.957M	$23.42M
YoY Change	137.82%	77.6%	116.05%
Total Long-Term Assets	$98.95M	$65.46M	$65.46M
YoY Change	111.59%	107.32%	107.32%
TOTAL ASSETS
Total Short-Term Assets	$425.6M	$454.0M	$454.0M
Total Long-Term Assets	$98.95M	$65.46M	$65.46M
Total Assets	$524.6M	$519.5M	$519.5M
YoY Change	7.96%	12.12%	12.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.280M	$4.805M	$4.805M
YoY Change	-11.57%	58.37%	58.37%
Accrued Expenses	$20.37M	$21.13M	$25.48M
YoY Change	39.11%	38.52%	52.98%
Deferred Revenue	$31.12M	$26.11M
YoY Change	59.97%	54.76%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$582.0K	$580.0K	$580.0K
YoY Change
Total Short-Term Liabilities	$56.52M	$49.04M	$49.04M
YoY Change	32.04%	47.8%	47.8%
LONG-TERM LIABILITIES
Long-Term Debt	$2.133M	$2.271M	$2.271M
YoY Change
Other Long-Term Liabilities	$1.867M	$1.587M	$42.62M
YoY Change	67.29%	31.81%	72.27%
Total Long-Term Liabilities	$1.867M	$1.587M	$44.89M
YoY Change	67.29%	31.81%	81.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$56.52M	$49.04M	$49.04M
Total Long-Term Liabilities	$1.867M	$1.587M	$44.89M
Total Liabilities	$101.1M	$93.93M	$94.18M
YoY Change	28.91%	62.17%	61.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$23.84M	-$17.03M
YoY Change	10.22%	-13.14%
Common Stock	$136.0K	$135.0K
YoY Change	1.49%	7.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$423.5M	$425.5M	$425.3M
YoY Change
Total Liabilities & Shareholders Equity	$524.6M	$519.5M	$519.5M
YoY Change	7.96%	12.12%	12.12%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$6.807M	$3.529M	$2.484M
YoY Change	215.43%	-396.31%	-17.94%
Depreciation, Depletion And Amortization	$1.001M	$761.0K	$2.492M
YoY Change	26.07%	11.09%	100.64%
Cash From Operating Activities	$2.858M	$6.193M	-$12.23M
YoY Change	93.11%	13.67%	-364.17%
INVESTING ACTIVITIES
Capital Expenditures	$505.0K	$6.610M	$9.748M
YoY Change	-35.26%	-610.03%	123.37%
Acquisitions
YoY Change
Other Investing Activities	-$168.4M	-$44.45M	-$46.04M
YoY Change		161.49%	176.87%
Cash From Investing Activities	-$168.9M	-$51.06M	-$55.91M
YoY Change	21550.51%	179.1%	166.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	3.850M	5.513M
YoY Change	-100.0%	22547.06%	-97.42%
NET CHANGE
Cash From Operating Activities	2.858M	6.193M	-12.23M
Cash From Investing Activities	-168.9M	-51.06M	-55.91M
Cash From Financing Activities	0.000	3.850M	5.513M
Net Change In Cash	-167.1M	-41.02M	-65.12M
YoY Change	7812.22%	219.7%	-132.81%
FREE CASH FLOW
Cash From Operating Activities	$2.858M	$6.193M	-$12.23M
Capital Expenditures	$505.0K	$6.610M	$9.748M
Free Cash Flow	$2.353M	-$417.0K	-$21.98M
YoY Change	236.14%	-106.18%	-8362.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001831915
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40632
CY2022	dei	Entity Registrant Name EntityRegistrantName	CYTEK BIOSCIENCES, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-2547526
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	47215 Lakeview Blvd.
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
CY2022	dei	City Area Code CityAreaCode	877
CY2022	dei	Local Phone Number LocalPhoneNumber	922-9835
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	CTKB
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	1300000000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	135430624
CY2022	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2022	dei	Auditor Location AuditorLocation	San Jose, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	296601000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	364618000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2899000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	44548000
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	0
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48864000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	29760000
CY2022Q4	us-gaap	Inventory Net InventoryNet	48154000
CY2021Q4	us-gaap	Inventory Net InventoryNet	32171000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12954000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5184000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	454020000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	431733000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	20459000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	9173000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13682000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5851000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13883000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2022Q4	us-gaap	Goodwill Goodwill	10144000
CY2021Q4	us-gaap	Goodwill Goodwill	10144000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4331000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4739000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2957000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1665000
CY2022Q4	us-gaap	Assets Assets	519476000
CY2021Q4	us-gaap	Assets Assets	463305000
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4805000
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3034000
CY2022Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	2163000
CY2021Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	1463000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21126000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15251000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7960000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6352000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12986000
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7081000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	49040000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33181000
CY2022Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	15596000
CY2021Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	13745000
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13124000
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9790000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12312000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2271000
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1587000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1204000
CY2022Q4	us-gaap	Liabilities Liabilities	93930000
CY2021Q4	us-gaap	Liabilities Liabilities	57920000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	133749663
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135365381
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135365381
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	133749663
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	135000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	126000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	442887000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	423625000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17030000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19606000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-697000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	897000
CY2022Q4	ctkb	Noncontrolling Interest In Consolidated Subsidiary NoncontrollingInterestInConsolidatedSubsidiary	251000
CY2021Q4	ctkb	Noncontrolling Interest In Consolidated Subsidiary NoncontrollingInterestInConsolidatedSubsidiary	343000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	425546000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	405385000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	519476000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	463305000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164036000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	127950000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92839000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	63062000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	48806000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	41129000
CY2022	us-gaap	Gross Profit GrossProfit	100974000
CY2021	us-gaap	Gross Profit GrossProfit	79144000
CY2020	us-gaap	Gross Profit GrossProfit	51710000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34858000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24442000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13693000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	33230000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	24710000
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14988000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34690000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20835000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9370000
CY2022	us-gaap	Operating Expenses OperatingExpenses	102778000
CY2021	us-gaap	Operating Expenses OperatingExpenses	69987000
CY2020	us-gaap	Operating Expenses OperatingExpenses	38051000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1804000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	9157000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	13659000
CY2022	us-gaap	Interest Expense InterestExpense	2573000
CY2021	us-gaap	Interest Expense InterestExpense	1741000
CY2020	us-gaap	Interest Expense InterestExpense	333000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	4619000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	49000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	110000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1018000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1527000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	994000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	771000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1260000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5938000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1224000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3064000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3219000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2911000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	14430000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4981000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2484000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	3027000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	19411000
CY2022	us-gaap	Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable	-92000
CY2021	us-gaap	Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable	26000
CY2020	us-gaap	Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable	0
CY2022	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0
CY2021	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	3001000
CY2020	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	16195000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2576000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	2576000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	0
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	0
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3216000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3216000
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.02
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.11
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.02
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0
CY2020	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.10
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134510831
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76741858
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29126792
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138562111
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81542729
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32599847
CY2022	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	2484000
CY2021	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	3027000
CY2020	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	19411000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1611000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	832000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-212000
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	17000
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	890000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3859000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	19623000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	41701000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	334000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	195000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	611000
CY2020	ctkb	Stock Issuance For Litigation Settlement Value StockIssuanceForLitigationSettlementValue	5244000
CY2020	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	212000
CY2020	ctkb	Net Income Loss1 NetIncomeLoss1	19411000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-16028000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	644000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6586000
CY2021	ctkb	Issuance Of Common Stock Upon Initial Public Offering Net Of Underwriting Discounts And Commissions And Other Offering Costs Value IssuanceOfCommonStockUponInitialPublicOfferingNetOfUnderwritingDiscountsAndCommissionsAndOtherOfferingCostsValue	215689000
CY2021	ctkb	Conversion Of Redeemable Convertible Preferred Stock To Common Stock Upon Initial Public Offering Value ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingValue	194318000
CY2021	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	832000
CY2021	ctkb	Net Income Loss1 NetIncomeLoss1	3027000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	317000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	405385000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2885000
CY2022	ctkb	Common Stock Withheld Related To Netshare Settlement CommonStockWithheldRelatedToNetshareSettlement	-209000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16595000
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	17000
CY2022	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	1611000
CY2022	ctkb	Net Income Loss1 NetIncomeLoss1	2576000
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-92000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	425546000
CY2022	us-gaap	Profit Loss ProfitLoss	2484000
CY2021	us-gaap	Profit Loss ProfitLoss	3027000
CY2020	us-gaap	Profit Loss ProfitLoss	19411000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2492000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1242000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	603000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3167000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0
CY2022	ctkb	Allowance For Doubtful Accounts AllowanceForDoubtfulAccounts	102000
CY2021	ctkb	Allowance For Doubtful Accounts AllowanceForDoubtfulAccounts	0
CY2020	ctkb	Allowance For Doubtful Accounts AllowanceForDoubtfulAccounts	175000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	16595000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	6586000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	611000
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	40000
CY2020	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0
CY2022	ctkb	Gain Loss On Sublease Contract GainLossOnSubleaseContract	0
CY2021	ctkb	Gain Loss On Sublease Contract GainLossOnSubleaseContract	-283000
CY2020	ctkb	Gain Loss On Sublease Contract GainLossOnSubleaseContract	0
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	756000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	488000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	1569000
CY2022	ctkb	Loss Gain On Investments Accretion And Amortization Net LossGainOnInvestmentsAccretionAndAmortizationNet	-77000
CY2021	ctkb	Loss Gain On Investments Accretion And Amortization Net LossGainOnInvestmentsAccretionAndAmortizationNet	0
CY2020	ctkb	Loss Gain On Investments Accretion And Amortization Net LossGainOnInvestmentsAccretionAndAmortizationNet	0
CY2022	ctkb	Interest Expenses For Accretion Of Legal Settlement Liabilities InterestExpensesForAccretionOfLegalSettlementLiabilities	2178000
CY2021	ctkb	Interest Expenses For Accretion Of Legal Settlement Liabilities InterestExpensesForAccretionOfLegalSettlementLiabilities	1690000
CY2020	ctkb	Interest Expenses For Accretion Of Legal Settlement Liabilities InterestExpensesForAccretionOfLegalSettlementLiabilities	323000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	19744000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12367000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-334000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	17653000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7068000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5704000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19362000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6252000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8216000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1862000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-256000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	55000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7470000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	10978000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3269000
CY2022	ctkb	Increase Decrease In Legal Settlement Liabilities IncreaseDecreaseInLegalSettlementLiabilities	373000
CY2021	ctkb	Increase Decrease In Legal Settlement Liabilities IncreaseDecreaseInLegalSettlementLiabilities	-3693000
CY2020	ctkb	Increase Decrease In Legal Settlement Liabilities IncreaseDecreaseInLegalSettlementLiabilities	458000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	9411000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	10012000
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2378000
CY2022	ctkb	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	2285000
CY2021	ctkb	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	0
CY2020	ctkb	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	0
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12231000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4630000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	15156000
CY2022	ctkb	Purchases Of Marketable Securities PurchasesOfMarketableSecurities	-44454000
CY2021	ctkb	Purchases Of Marketable Securities PurchasesOfMarketableSecurities	0
CY2020	ctkb	Purchases Of Marketable Securities PurchasesOfMarketableSecurities	0
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9748000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4364000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1547000
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	17000000
CY2020	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	120000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2022	us-gaap	Payments To Acquire Real Estate Held For Investment PaymentsToAcquireRealEstateHeldForInvestment	1587000
CY2021	us-gaap	Payments To Acquire Real Estate Held For Investment PaymentsToAcquireRealEstateHeldForInvestment	0
CY2020	us-gaap	Payments To Acquire Real Estate Held For Investment PaymentsToAcquireRealEstateHeldForInvestment	0
CY2022	ctkb	Payment For Additional Investment In Cytek Japan Net Of Cash Acquired PaymentForAdditionalInvestmentInCytekJapanNetOfCashAcquired	0
CY2021	ctkb	Payment For Additional Investment In Cytek Japan Net Of Cash Acquired PaymentForAdditionalInvestmentInCytekJapanNetOfCashAcquired	-371000
CY2020	ctkb	Payment For Additional Investment In Cytek Japan Net Of Cash Acquired PaymentForAdditionalInvestmentInCytekJapanNetOfCashAcquired	0
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-55909000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20993000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1547000
CY2022	ctkb	Proceeds From Paycheck Protection Program Loan ProceedsFromPaycheckProtectionProgramLoan	0
CY2021	ctkb	Proceeds From Paycheck Protection Program Loan ProceedsFromPaycheckProtectionProgramLoan	0
CY2020	ctkb	Proceeds From Paycheck Protection Program Loan ProceedsFromPaycheckProtectionProgramLoan	4082000
CY2022	ctkb	Repayment Of Paycheck Protection Program Loan RepaymentOfPaycheckProtectionProgramLoan	0
CY2021	ctkb	Repayment Of Paycheck Protection Program Loan RepaymentOfPaycheckProtectionProgramLoan	2772000
CY2020	ctkb	Repayment Of Paycheck Protection Program Loan RepaymentOfPaycheckProtectionProgramLoan	1310000
CY2022	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0
CY2021	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	119666000
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	215689000
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2983000
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	50000
CY2022	ctkb	Proceeds From Employee Stock Purchase Plans ProceedsFromEmployeeStockPurchasePlans	1585000
CY2021	ctkb	Proceeds From Employee Stock Purchase Plans ProceedsFromEmployeeStockPurchasePlans	0
CY2020	ctkb	Proceeds From Employee Stock Purchase Plans ProceedsFromEmployeeStockPurchasePlans	0
CY2022	ctkb	Payments For Taxes Related To Net Share Settlement Of Equity Awards PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards	209000
CY2021	ctkb	Payments For Taxes Related To Net Share Settlement Of Equity Awards PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards	0
CY2020	ctkb	Payments For Taxes Related To Net Share Settlement Of Equity Awards PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards	0
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1204000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	642000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	169000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5513000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	213559000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	122607000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2491000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1303000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-587000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-65118000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	198499000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	135629000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	364618000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	166119000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30490000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299500000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	364618000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	166119000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	10390000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2863000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2073000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	67000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	134000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2022	ctkb	Intangible Asset In Accrued Expense IntangibleAssetInAccruedExpense	30000
CY2021	ctkb	Intangible Asset In Accrued Expense IntangibleAssetInAccruedExpense	93000
CY2020	ctkb	Intangible Asset In Accrued Expense IntangibleAssetInAccruedExpense	0
CY2022	ctkb	Non Cash Investing And Financing Activities Stock Option Exercise In Accounts Receivable At Period End NonCashInvestingAndFinancingActivitiesStockOptionExerciseInAccountsReceivableAtPeriodEnd	96000
CY2021	ctkb	Non Cash Investing And Financing Activities Stock Option Exercise In Accounts Receivable At Period End NonCashInvestingAndFinancingActivitiesStockOptionExerciseInAccountsReceivableAtPeriodEnd	0
CY2020	ctkb	Non Cash Investing And Financing Activities Stock Option Exercise In Accounts Receivable At Period End NonCashInvestingAndFinancingActivitiesStockOptionExerciseInAccountsReceivableAtPeriodEnd	26000
CY2022	ctkb	Proceeds From Issuance Of Common Stock For Legal Settlement ProceedsFromIssuanceOfCommonStockForLegalSettlement	0
CY2021	ctkb	Proceeds From Issuance Of Common Stock For Legal Settlement ProceedsFromIssuanceOfCommonStockForLegalSettlement	0
CY2020	ctkb	Proceeds From Issuance Of Common Stock For Legal Settlement ProceedsFromIssuanceOfCommonStockForLegalSettlement	5244000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Description of business </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Cytek Biosciences, Inc. (“Cytek” or the “Company”) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. The Company has focused on becoming the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company has successfully developed and manufactured its full spectrum flow cytometry platform (“instrument(s)” or “product(s)”). The Company believes its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling” or “FSP”). The Company’s FSP platform includes instruments, accessories, reagents, software, and services to provide a comprehensive and integrated suite of solutions for its customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company was incorporated in the state of </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Delaware</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> in December 2014 and is headquartered in Fremont, California with offices, manufacturing facilities and distribution channels across the globe.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In July 2021, the Company priced its initial public offering (“IPO”) of </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13,949,401</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of common stock, which included the full exercise by the underwriters of their option to purchase an additional </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,184,695</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares from the Company, at an initial public offering price of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">237.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, which resulted in net proceeds to the Company of approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">215.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions of approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million and offering-related transaction costs of approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million. In addition, certain selling stockholders offered and sold an additional </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,799,929</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares or common stock in the IPO. The Company did </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">t receive any proceeds from the sale of such shares by the selling stockholders.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In addition, in connection with the completion of the IPO on July 27, 2021, all outstanding shares of convertible preferred stock (see Note 11) were automatically converted into </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">87,268,694</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of the Company’s common stock and were reclassified as permanent equity. Further, immediately following the closing of the IPO, the Company amended and restated its certificate of incorporation such that the total number of shares of common stock authorized to be issued was </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,000,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> and the total number of shares of preferred stock authorized to be issued was </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. Following the IPO, there are </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of convertible preferred stock outstanding</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Shelf Registration Statement and At-the-Market Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On August 26, 2022, the Company filed with the SEC an automatic shelf registration statement on Form S-3ASR (File No. 333-267118) (the “Registration Statement”). In connection with the filing of the Registration Statement, the Company also entered into a sales agreement (the “2022 Sales Agreement”) with Piper Sandler & Co. (“Piper”) as sales agent to sell from time to time up to $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">150</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million of the Company’s common stock through an “at-the-market” offering program as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Pursuant to the terms of the 2022 Sales Agreement, the aggregate compensation payable to Piper is up to </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the gross proceeds from the sale of common stock sold by Piper pursuant to the 2022 Sales Agreement. Each party agreed in the 2022 Sale Agreement to provide indemnification and contribution against certain liabilities, including liabilities under the Securities Act, subject to the terms of the 2022 Sales Agreement. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company has not made any sales of common stock pursuant to the 2022 Sales Agreement.</span></p>
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.50
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes as of the date of the consolidated financial statements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</span>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	296600000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	364600000
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000
CY2021Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000
CY2022Q4	us-gaap	Cash Cash	123371000
CY2021Q4	us-gaap	Cash Cash	18939000
CY2022Q4	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	29930000
CY2021Q4	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	345679000
CY2022Q4	us-gaap	Us Government Agencies Securities At Carrying Value USGovernmentAgenciesSecuritiesAtCarryingValue	19908000
CY2021Q4	us-gaap	Us Government Agencies Securities At Carrying Value USGovernmentAgenciesSecuritiesAtCarryingValue	0
CY2022Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	5955000
CY2021Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	0
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	117437000
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	0
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	2899000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	0
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299500000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	364618000
CY2022	us-gaap	Financing Receivable Allowance For Credit Losses Policy For Uncollectible Amounts FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Allowance for uncollectible receivables</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company adopted ASU 2016-13, Financial Instruments - Credit Losses, on December 31, 2022, which was retroactively applied as of the first day of fiscal year 2022, as further described within the section below titled Recently Adopted Accounting Pronouncements. This accounting standard requires companies to measure expected credit losses on financial instruments based on the total estimated amount to be collected over the lifetime of the instrument. Prior to the adoption of this accounting standard, the Company recorded incurred loss reserves against receivable balances based on current and historical information.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Expected credit losses for uncollectible receivable balances consider both current conditions and reasonable and supportable forecasts of future conditions. Current conditions considered include pre-defined aging criteria, as well as specified events that indicate the balance due is not collectible. Reasonable and supportable forecasts used in determining the probability of future collection consider publicly available macroeconomic data and whether future credit losses are expected to differ from historical losses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is not party to any off-balance sheet arrangements that would require an allowance for credit losses in accordance with this accounting standard.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The changes in the allowance for uncollectible receivables for the year ended December 31, 2022 were as follows (in thousands):</span></p><div style="font-size:10.0pt;font-family:"Times New Roman", serif;"> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:76.248%;"/> <td style="width:1.942%;"/> <td style="width:1.0%;"/> <td style="width:19.811%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Allowance for doubtful accounts</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Cumulative effect adjustment upon adoption of ASU 2016-13</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Balance at January 1, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Utilization of allowance for doubtful accounts</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Provision for credit losses</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">102</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">102</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></div>
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3000
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3000
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	3000
CY2022	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	102000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	102000
CY2022	ctkb	Upfront And Payment Terms UpfrontAndPaymentTerms	P30D
CY2021Q3	ctkb	Offering Related Transaction Costs OfferingRelatedTransactionCosts	5300000
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2500000
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1800000
CY2022Q4	ctkb	Customer Deposit Liability Current CustomerDepositLiabilityCurrent	1555000
CY2021Q4	ctkb	Customer Deposit Liability Current CustomerDepositLiabilityCurrent	1018000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17889000
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5253000
CY2020	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	10678000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14600000
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	15200000
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	26110000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48864000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	29760000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	26110000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16871000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	27665000
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	13170000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7745000
CY2021	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	15008000
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	25152000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17889000
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	24686000
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	34462000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	27665000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	26925000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	17260000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4897000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2297000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	16332000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	12614000
CY2022Q4	us-gaap	Inventory Gross InventoryGross	48154000
CY2021Q4	us-gaap	Inventory Gross InventoryGross	32171000
CY2022Q4	ctkb	Prepaid Inventory PrepaidInventory	621000
CY2021Q4	ctkb	Prepaid Inventory PrepaidInventory	397000
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	293000
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	201000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1466000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1873000
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	2080000
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	0
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2687000
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2132000
CY2022Q4	ctkb	Tax Refund Receivable And Payable TaxRefundReceivableAndPayable	2011000
CY2021Q4	ctkb	Tax Refund Receivable And Payable TaxRefundReceivableAndPayable	-127000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3796000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	708000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12954000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5184000
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	13911000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	9117000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1276000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1119000
CY2022Q4	ctkb	Accrued Purchases AccruedPurchases	2457000
CY2021Q4	ctkb	Accrued Purchases AccruedPurchases	2483000
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2126000
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1760000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1356000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	772000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	21126000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	15251000
CY2022Q4	ctkb	Customer Deposit Liability Current CustomerDepositLiabilityCurrent	1555000
CY2021Q4	ctkb	Customer Deposit Liability Current CustomerDepositLiabilityCurrent	1018000
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	246000
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2476000
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1421000
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1403000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2931000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2022Q4	us-gaap	Long Term Construction Loan Current LongTermConstructionLoanCurrent	580000
CY2021Q4	us-gaap	Long Term Construction Loan Current LongTermConstructionLoanCurrent	0
CY2022Q4	ctkb	Other Current Liabilities Other OtherCurrentLiabilitiesOther	1227000
CY2021Q4	ctkb	Other Current Liabilities Other OtherCurrentLiabilitiesOther	1455000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7960000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6352000
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	345679000
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	217778000
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1600000
CY2022Q4	ctkb	Cashandcashequivalentsamortizedcostbasis Cashandcashequivalentsamortizedcostbasis	44532000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	18000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000
CY2022Q4	us-gaap	Financial Instruments Owned Derivatives And Other Contractual Agreements At Fair Value FinancialInstrumentsOwnedDerivativesAndOtherContractualAgreementsAtFairValue	44549000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	824000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4331000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5563000
CY2022Q4	ctkb	Cashandcashequivalentsamortizedcostbasis Cashandcashequivalentsamortizedcostbasis	44532000
CY2022Q4	us-gaap	Financial Instruments Owned Derivatives And Other Contractual Agreements At Fair Value FinancialInstrumentsOwnedDerivativesAndOtherContractualAgreementsAtFairValue	44549000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16841000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7711000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3159000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1860000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13682000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5851000
CY2022	us-gaap	Depreciation Depreciation	1700000
CY2021	us-gaap	Depreciation Depreciation	900000
CY2020	us-gaap	Depreciation Depreciation	500000
CY2022	ctkb	Schedule Of Identifiable Intangible Assets Acquired And Their Estimated Useful Lives For Amortization ScheduleOfIdentifiableIntangibleAssetsAcquiredAndTheirEstimatedUsefulLivesForAmortization	<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows:</span> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.409%;"/> <td style="width:1.0%;"/> <td style="width:23.471%;"/> <td style="width:1.0%;"/> <td style="width:3.249%;"/> <td style="width:29.871%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Tonbo</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Useful life (years)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">(In thousands, except for years)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Customer relationships</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,200</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Reagent licenses</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,800</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Tradename</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">700</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,700</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2022Q4	ctkb	Royalty Rates RoyaltyRates	0.020
CY2022Q4	ctkb	Discount Rate DiscountRate	0.130
CY2021Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	230000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5710000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1379000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4739000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	835000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	334000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	71000
CY2022	us-gaap	Loss Contingency Lawsuit Filing Date LossContingencyLawsuitFilingDate	February 13, 2018
CY2022	ctkb	Upfront Payment UpfrontPayment	2000000.0
CY2022	ctkb	Royalty Payment Duration RoyaltyPaymentDuration	P10Y
CY2022	ctkb	Mile Stone Payment MileStonePayment	6000000.0
CY2022	ctkb	Cost Of Sales Related To Royalty Expense CostOfSalesRelatedToRoyaltyExpense	600000
CY2021	ctkb	Cost Of Sales Related To Royalty Expense CostOfSalesRelatedToRoyaltyExpense	3300000
CY2020	ctkb	Cost Of Sales Related To Royalty Expense CostOfSalesRelatedToRoyaltyExpense	2500000
CY2022	us-gaap	Litigation Settlement Interest LitigationSettlementInterest	2200000
CY2021	us-gaap	Litigation Settlement Interest LitigationSettlementInterest	1700000
CY2020	us-gaap	Litigation Settlement Interest LitigationSettlementInterest	300000
CY2022Q4	ctkb	Legal Settlement Liability Current LegalSettlementLiabilityCurrent	2163000
CY2021Q4	ctkb	Legal Settlement Liability Current LegalSettlementLiabilityCurrent	1463000
CY2022Q4	ctkb	Legal Settlement Liability Non Current LegalSettlementLiabilityNonCurrent	15596000
CY2021Q4	ctkb	Legal Settlement Liability Non Current LegalSettlementLiabilityNonCurrent	13745000
CY2022Q4	ctkb	Legal Settlement Liability LegalSettlementLiability	17759000
CY2021Q4	ctkb	Legal Settlement Liability LegalSettlementLiability	15208000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6174778
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.67
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M14D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11405000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4344187
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.99
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1289652
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.51
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	417797
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.05
CY2021	ctkb	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod	5666
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.39
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8805850
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.56
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	147623000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	715352
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.43
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1224564
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.07
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	641036
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.85
CY2022	ctkb	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod	76967
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.33
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7578635
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.76
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M1D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	37200000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4219843
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.89
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y7M20D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	28852000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.21
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.42
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.97
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16595000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6586000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	611000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1045000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	770000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	584000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1347000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1870000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	14136000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2607000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	7808000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	294000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1260000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5938000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	14430000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	7280000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	3666000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1108000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1339000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	440000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	580000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1442000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	601000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	709000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	10061000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4707000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2397000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-9164000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2529000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4956000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1910000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-579000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1086000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-211000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	1312000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1336000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-11285000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1796000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7378000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1224000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2911000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4981000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.600
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.039
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.055
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.379
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.096
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.037
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.392
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.039
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.015
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	1.464
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.066
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.024
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0.894
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0.078
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0.011
CY2022	ctkb	Effective Income Tax Rate Reconciliation Subpart EffectiveIncomeTaxRateReconciliationSubpart	0.672
CY2021	ctkb	Effective Income Tax Rate Reconciliation Subpart EffectiveIncomeTaxRateReconciliationSubpart	0.231
CY2020	ctkb	Effective Income Tax Rate Reconciliation Subpart EffectiveIncomeTaxRateReconciliationSubpart	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.071
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.217
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.007
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.019
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.010
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.032
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.471
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.006
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.019
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.606
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.011
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.534
CY2022	ctkb	Effective Income Tax Rate Reconciliation Compensation EffectiveIncomeTaxRateReconciliationCompensation	0.044
CY2021	ctkb	Effective Income Tax Rate Reconciliation Compensation EffectiveIncomeTaxRateReconciliationCompensation	0
CY2020	ctkb	Effective Income Tax Rate Reconciliation Compensation EffectiveIncomeTaxRateReconciliationCompensation	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0.196
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.022
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.005
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.971
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.489
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.345
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	755000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	632000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	492000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	430000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	904000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	155000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1578000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	4050000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	3544000
CY2022Q4	ctkb	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	4415000
CY2021Q4	ctkb	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	2595000
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	4948000
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	0
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	881000
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	792000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1236000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	776000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	3108000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	1510000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	25755000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10434000
CY2022Q4	ctkb	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	3388000
CY2021Q4	ctkb	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	0
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1248000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	483000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	24507000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9951000
CY2022Q4	ctkb	Deferred Tax Liabilities Accounting Method Change DeferredTaxLiabilitiesAccountingMethodChange	0
CY2021Q4	ctkb	Deferred Tax Liabilities Accounting Method Change DeferredTaxLiabilitiesAccountingMethodChange	-196000
CY2022Q4	ctkb	Deferred Tax Liabilities Right Of Use Of Assets DeferredTaxLiabilitiesRightOfUseOfAssets	-3053000
CY2022Q4	ctkb	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	-995000
CY2021Q4	ctkb	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	-581000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4048000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	777000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	20459000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	9174000
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	The state net operating loss begins to expire in 2036 if not utilized.
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1321000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	737000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	234000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	298000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	65000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	77000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	616000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	519000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	426000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2235000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1321000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	737000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2200000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1300000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	700000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2000000.0
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1100000
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	600000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	3539000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	48000
CY2022	us-gaap	Lease Cost LeaseCost	3587000
CY2022	us-gaap	Sublease Income SubleaseIncome	266000
CY2022	ctkb	Operating Cash Outflows Payments On Operating Leases OperatingCashOutflowsPaymentsOnOperatingLeases	2332000
CY2022	ctkb	Right Of Use Assets Obtained In Exchange For New Lease Obligations RightOfUseAssetsObtainedInExchangeForNewLeaseObligations	16852000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13883000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2931000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12312000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	15243000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y5M19D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.026
CY2020Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	969000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3278000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3106000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2683000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2578000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2315000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2395000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	16355000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1112000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	15243000
CY2021Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions FutureMinimumSubleaseRentalsSaleLeasebackTransactions	600000
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Rolling Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextRollingTwelveMonths	2251000
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Rolling Year Two LessorOperatingLeasePaymentsToBeReceivedRollingYearTwo	2803000
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Rolling Year Three LessorOperatingLeasePaymentsToBeReceivedRollingYearThree	2417000
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Rolling Year Four LessorOperatingLeasePaymentsToBeReceivedRollingYearFour	2215000
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Rolling Year Five LessorOperatingLeasePaymentsToBeReceivedRollingYearFive	2220000
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received After Rolling Year Five LessorOperatingLeasePaymentsToBeReceivedAfterRollingYearFive	4571000
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	16477000
CY2022	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	2841000
CY2021	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	3304000
CY2022	us-gaap	Product Warranty Expense ProductWarrantyExpense	2475000
CY2020Q2	us-gaap	Proceeds From Loan Originations1 ProceedsFromLoanOriginations1	4100000
CY2020Q2	ctkb	Average Monthly Payroll Expense AverageMonthlyPayrollExpense	2.5
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	92000
CY2021	us-gaap	Change In Reporting Entity Income Loss After Tax Attributable To Parent ChangeInReportingEntityIncomeLossAfterTaxAttributableToParent	26000
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1760000
CY2021	us-gaap	Product Warranty Expense ProductWarrantyExpense	2513000
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2126000
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1760000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2484000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	3027000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	19411000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	92000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-26000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2022	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0
CY2021	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	3001000
CY2020	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	16195000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2576000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	0
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3216000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134510831
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76741858
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29126792
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	4051280
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	4800871
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3473055
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138562111
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81542729
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32599847
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2021	us-gaap	Revenues Revenues	2181000
CY2020	us-gaap	Revenues Revenues	710000
CY2022	us-gaap	Revenues Revenues	164036000
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	13682000
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	5851000
CY2022	dei	Auditor Firm AuditorFirmId	34

Files In Submission

Name	View Source	Status
0000950170-23-005610-index-headers.html	Edgar Link	pending
0000950170-23-005610-index.html	Edgar Link	pending
0000950170-23-005610.txt	Edgar Link	pending
0000950170-23-005610-xbrl.zip	Edgar Link	pending
ctkb-20221231.htm	Edgar Link	pending
ctkb-20221231.xsd	Edgar Link	pending
ctkb-ex10_16.htm	Edgar Link	pending
ctkb-ex21_1.htm	Edgar Link	pending
ctkb-ex23_1.htm	Edgar Link	pending
ctkb-ex31_1.htm	Edgar Link	pending
ctkb-ex31_2.htm	Edgar Link	pending
ctkb-ex32_1.htm	Edgar Link	pending
ctkb-ex32_2.htm	Edgar Link	pending
ctkb-ex4_3.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img104188130_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
ctkb-20221231_cal.xml	Edgar Link	unprocessable
ctkb-20221231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ctkb-20221231_lab.xml	Edgar Link	unprocessable
ctkb-20221231_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ctkb-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTKB
Cytek Biosciences, Inc. Stock $ctkb

2023 Q1 Form 10-K Financial Statement

#000095017023005610 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTKB Cytek Biosciences, Inc. Stock $ctkb

2023 Q1 Form 10-K Financial Statement

#000095017023005610 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTKB
Cytek Biosciences, Inc. Stock $ctkb